Almawash S
Cancers (Basel). 2025; 17(5).
PMID: 40075727
PMC: 11899125.
DOI: 10.3390/cancers17050880.
Nisar M, Yan T, Cai Y, Wan C
Probiotics Antimicrob Proteins. 2025; .
PMID: 39954194
DOI: 10.1007/s12602-025-10468-8.
Gao C, Chen L, Zhao L, Su Y, Ma M, Zhang W
Cancers (Basel). 2025; 17(3).
PMID: 39941891
PMC: 11816266.
DOI: 10.3390/cancers17030524.
Xue H, Chen Y, Zhou Y
Front Immunol. 2024; 15:1522508.
PMID: 39712010
PMC: 11659256.
DOI: 10.3389/fimmu.2024.1522508.
Patel M, Falchook G, Wang J, Imedio E, Kumar S, Miah K
Target Oncol. 2024; 20(1):127-138.
PMID: 39560862
PMC: 11762568.
DOI: 10.1007/s11523-024-01110-8.
Comprehensive analysis to identify IL7R as a immunotherapy biomarker from pan-cancer analysis to in vitro validation.
Liang J, Zhu L, Li J, Wu K, Zhang M, Ma S
Discov Oncol. 2024; 15(1):509.
PMID: 39347891
PMC: 11442881.
DOI: 10.1007/s12672-024-01357-7.
Biological Agents for Treating Atezolizumab-Induced Psoriasis in Small-Cell Lung Cancer: A Case Report.
Fukui M, Chihara Y, Takahashi Y, Sai N, Doi H, Nakakubo Y
Cureus. 2024; 16(5):e61395.
PMID: 38947665
PMC: 11214649.
DOI: 10.7759/cureus.61395.
Hepatocellular Carcinoma and the Multifaceted Relationship with Its Microenvironment: Attacking the Hepatocellular Carcinoma Defensive Fortress.
Galasso L, Cerrito L, Maccauro V, Termite F, Ainora M, Gasbarrini A
Cancers (Basel). 2024; 16(10).
PMID: 38791916
PMC: 11119751.
DOI: 10.3390/cancers16101837.
Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
Sharma S, Singh N, Turk A, Wan I, Guttikonda A, Dong J
World J Gastroenterol. 2024; 30(13):1815-1835.
PMID: 38659481
PMC: 11036501.
DOI: 10.3748/wjg.v30.i13.1815.
Risk of interstitial lung disease with the use of programmed cell death 1 (PD-1) inhibitor compared with programmed cell death ligand 1 (PD-L1) inhibitor in patients with breast cancer: A systematic review and meta-analysis.
Guo L, Lin X, Lin X, Wang Y, Lin J, Zhang Y
Cancer Pathog Ther. 2024; 2(2):91-102.
PMID: 38601483
PMC: 11002750.
DOI: 10.1016/j.cpt.2023.08.002.
The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review.
Guven D, Kavgaci G, Erul E, Syed M, Magge T, Saeed A
Oncologist. 2024; 29(5):e580-e600.
PMID: 38309719
PMC: 11067816.
DOI: 10.1093/oncolo/oyae013.
Biophysical Control of the Glioblastoma Immunosuppressive Microenvironment: Opportunities for Immunotherapy.
Teer L, Yaddanapudi K, Chen J
Bioengineering (Basel). 2024; 11(1).
PMID: 38247970
PMC: 10813491.
DOI: 10.3390/bioengineering11010093.
The role of intestinal flora on tumor immunotherapy: recent progress and treatment implications.
Zhou Y, Liu X, Gao W, Luo X, Lv J, Wang Y
Heliyon. 2024; 10(1):e23919.
PMID: 38223735
PMC: 10784319.
DOI: 10.1016/j.heliyon.2023.e23919.
Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review.
Fujiwara M, Shimizu M, Okano T, Maejima Y, Shimomura K
Front Public Health. 2023; 11:1264056.
PMID: 38106883
PMC: 10725247.
DOI: 10.3389/fpubh.2023.1264056.
Development of a human glioblastoma model using humanized DRAG mice for immunotherapy.
Srivastava R, Labani-Motlagh A, Chen A, Bohorquez J, Qin B, Dodda M
Antib Ther. 2023; 6(4):253-264.
PMID: 38075240
PMC: 10702851.
DOI: 10.1093/abt/tbad021.
Unraveling the Intricacies of CD73/Adenosine Signaling: The Pulmonary Immune and Stromal Microenvironment in Lung Cancer.
Saigi M, Mesia-Carbonell O, Barbie D, Guillamat-Prats R
Cancers (Basel). 2023; 15(23).
PMID: 38067409
PMC: 10705793.
DOI: 10.3390/cancers15235706.
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.
VanderWalde A, Bellasea S, Kendra K, Khushalani N, Campbell K, Scumpia P
Nat Med. 2023; 29(9):2278-2285.
PMID: 37592104
PMC: 10708907.
DOI: 10.1038/s41591-023-02498-y.
Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma.
Sarfraz H, Saha A, Jhaveri K, Kim D
Curr Oncol. 2023; 30(6):5322-5336.
PMID: 37366887
PMC: 10296812.
DOI: 10.3390/curroncol30060404.
Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
Wu S, Ruan D, Wu Q, Tang Y, Zhang J, Cai S
J Hepatocell Carcinoma. 2023; 10:807-820.
PMID: 37292114
PMC: 10244613.
DOI: 10.2147/JHC.S408819.
Management of Advanced Prostate Cancer in the Precision Oncology Era.
Gillette C, Yette G, Cramer S, Graham L
Cancers (Basel). 2023; 15(9).
PMID: 37174018
PMC: 10177563.
DOI: 10.3390/cancers15092552.
